Sema Domain, Transmembrane Domain (TM), and Cytoplasmic Domain, (Semaphorin) 6A (SEMA6A) (N-Term), (AA 29-57) antibody

Details for Product No. ABIN650714
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Synonyms 9330158E07, A730020P05Rik, AI851735, Sema6A-1, Semaq, VIa, b2b997Clo, HT018, SEMA, SEMA6A1, SEMAQ, VIA, fj46c12, wu:fj46c12, zgc:66106, SEMA6A
Epitope
N-Term, AA 29-57
(4), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1)
Reactivity
Human
(48), (20), (18), (17), (17), (17)
Host
Rabbit
(31), (22), (1)
Clonality (Clone)
Polyclonal ()
Conjugate
Un-conjugated
(5), (5), (4), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Application
Western Blotting (WB)
(21), (21), (10), (10), (7), (6), (6), (4), (2), (2), (1)
Pubmed 1 reference available
Catalog no. ABIN650714
Quantity 400 µL
Price
291.50 $   Plus shipping costs $45.00
Options
Shipping to United States (Change)
Availability Will be delivered in 2 to 3 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen This SEMA6A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 29-57 AA from the N-terminal region of human SEMA6A.
Clone RB21218
Isotype Ig
Specificity This SEMA6A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 36-65 amino acids from the N-terminal region of human SEMA6A.
Predicted Reactivity Mouse (Murine)
Purification This antibody is purified through a protein A column, followed by peptide affinity purification.
Alternative Name SEMA6A
Background SEMA6A belongs to a subfamily characterized by an extracellular semaphorin domain, a transmembrane domain, and a long cytoplasmic tail. Members of this class can repel sympathetic and dorsal root ganglion axons in vitro, consistent with a traditional role as guidance signals. However, the length of the cytoplasmic tail, which includes an EVL-binding site in SEMA6A and an Src-binding site in SEMA6B, suggests that these semaphorins may also function as receptors. SEMA6A is expressed in developing neural tissue and is required for proper development of the thalamocortical projection. SEMA6A directly links the Ena/VASP and the semaphorin protein families since the SEMA6A protein is capable of selective binding to the protein EVL (Ena/VASP-like protein).
Synonyms: Semaphorin-6A,SEMA6A,SEMAQ, KIAA1368
Molecular Weight 114369 DA
Gene ID 57556
UniProt Q9H2E6, NP_065847.1
Application Notes WB = 1:1000
Restrictions For Research Use only
Format Liquid
Concentration 0.5 mg/mL
Buffer PBS with 0.09 % (W/V) sodium azide
Preservative Sodium azide
Storage 4 °C/-20 °C
Storage Comment Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
Expiry Date 6 months
Supplier Images
anti-Sema Domain, Transmembrane Domain (TM), and Cytoplasmic Domain, (Semaphorin) 6A (SEMA6A) (N-Term), (AA 29-57) antibody SEMA6A Antibody (N-term) (ABIN650714) western blot analysis in A2058 cell line lysates (15 µg/lane).This demonstrates the SEMA6A antibody detected the SEMA6A protein (arrow).
Background publications Landers, Melki, Meininger et al.: "Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, Issue 22, pp. 9004-9, 2009 (PubMed).

Hosts (31), (22), (1)
Reactivities (48), (20), (18), (17), (17), (17)
Applications (21), (21), (10), (10), (7), (6), (6), (4), (2), (2), (1)
Conjugates (5), (5), (4), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Epitopes (4), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1)
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Validation Images
back to top